One-Third of PCPs Discuss Breast Cancer Treatments With Patients
FRIDAY, Feb. 22, 2019 -- One-third of primary care providers (PCPs) report participating in breast cancer treatment decisions, according to a study published online Feb. 1 in Cancer.
Lau
FDA Approves Keytruda (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
KENILWORTH, N.J.--(BUSINESS WIRE) February 19, 2019 --Merck (NYSE: MRK), known as MSD outside the
FDA Approves Esperoct
FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A
Bagsværd, Denmark, 19 February 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Applicatio
Discharge Opioid Rx for Heart Dz Patients May Impact Follow-Up
FRIDAY, Feb. 15, 2019 -- For patients with an admitting diagnosis of acute coronary syndrome and/or acute decompensated heart failure, opioid prescription at discharge is not significantly as
FDA Approves Egaten (triclabendazole) for the Treatment of Fascioliasis, a Neglected Tropical Disease
Basel, Switzerland, February 13, 2019 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole)
FDA Approves Darzalex (daratumumab) Split-Dosing Regimen
Horsham, PA, February 12, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a split-dosing regimen for D